Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

AnaptysBio, Inc.

http://www.anaptysbio.com/

Latest From AnaptysBio, Inc.

Doubts Raised Over Regeneron’s Anti-IL 33 REGN3500 At Phase II In Asthma

Topline data from a Phase II proof-of-concept study evaluating anti-IL-33 monotherapy REGN3500 (SAR440340) in asthma suggest it is not as effective as Dupixent and that there is no incremental benefit from adding it to Dupixent.

Clinical Trials Companies

Galderma’s First-In-Class Biologic Chases Eczema Spoils

Galderma’s novel biologic is heading for Phase III studies in moderate-to-severe atopic dermatitis as the race to join Dupixent in an expanding market hots up.

Clinical Trials Dermatology

Finance Watch: With The Year's Biggest IPO, CFO Says Allogene Is Ready To Go 'Full Throttle'

Allogene launched a $324m IPO to fund development of its allogeneic CAR-T pipeline, bringing its 2018 fundraising total to $744m. Also, GW Pharma's $345m offering tops recent follow-ons.

Financing Business Strategies

Pipeline Watch: Phase III Progress With Semaglutide, Tecentriq And Epidaza

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register